13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
92 檔
55.1%
During the Q1 2024 filing period, Sectoral Asset Management Inc (CIK: 0001274413) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $143.3M across 92 reported positions.
During Q1 2024, Sectoral Asset Management Inc's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | Stock-Other | 9.38% | — | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.85% | +0.48% | -3.39% | |
| 3 | BOLD | Boundless Bio Inc | Stock-Other | 4.79% | -0.62% | EXIT | |
| 4 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 4.51% | +0.49% | +22.46% | |
| 5 | MRK | Merck & Co. Inc. | Stock-Healthcare | 4.49% | -0.20% | +8.80% | |
| 6 | ABT | Abbott Laboratories | Stock-Healthcare | 3.14% | -1.04% | +1.81% | |
| 7 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.98% | -0.46% | -11.14% | |
| 8 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.80% | -0.47% | -8.81% | |
| 9 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.68% | -1.12% | +84.48% | |
| 10 | ABBV | Abbvie Inc | Stock-Healthcare | 2.52% | -0.06% | -23.97% | |
| 11 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.33% | -0.73% | -5.47% | |
| 12 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.29% | -0.20% | +11.09% | |
| 13 | PFE | Pfizer Inc | Stock-Healthcare | 2.07% | -0.18% | — | |
| 14 | AMGN | Amgen Inc | Stock-Healthcare | 1.80% | -0.58% | -43.93% | |
| 15 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.77% | -0.12% | +3.14% | |
| 16 | DXCM | Dexcom Inc | Stock-Healthcare | 1.77% | +1.18% | +10.20% | |
| 17 | DHR | Danaher CORP | Stock-Healthcare | 1.74% | -0.23% | +18.36% | |
| 18 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 1.54% | — | — | |
| 19 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.44% | -0.44% | -7.18% | |
| 20 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.40% | +0.29% | -15.06% | |
| 21 | MDT | Medtronic plc | Stock-Healthcare | 1.30% | -0.19% | -4.99% | |
| 22 | PODD | Insulet CORP | Stock-Healthcare | 1.22% | — | +39.77% | |
| 23 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.18% | -0.98% | -21.79% | |
| 24 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.17% | +0.52% | +507.20% | |
| 25 | PGNY | Progyny Inc | Stock-Other | 1.14% | — | — | |
| 26 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.11% | -1.60% | -5.38% | |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.08% | -0.23% | -18.46% | |
| 28 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.05% | — | -22.15% | |
| 29 | CNC | Centene CORP | Stock-Healthcare | 1.05% | +0.54% | NEW | |
| 30 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.02% | — | +41.00% | |
| 31 | NARIUSD | Inari Medical Inc | Stock-Other | 0.99% | — | — | |
| 32 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.96% | -0.38% | — | |
| 33 | SYK | Stryker CORP | Stock-Healthcare | 0.93% | -0.03% | — | |
| 34 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.91% | — | +54.29% | |
| 35 | GDRX | Goodrx Holdings Inc-class A | Stock-Other | 0.90% | — | -11.81% | |
| 36 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.88% | — | -19.73% | |
| 37 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.84% | — | — | |
| 38 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.82% | -0.39% | -42.35% | |
| 39 | ARVN | Arvinas Inc | Stock-Other | 0.79% | — | -26.09% | |
| 40 | VERA | Vera Therapeutics Inc | Stock-Other | 0.76% | -0.13% | -63.83% | |
| 41 | EYPT | Eyepoint Inc | Stock-Other | 0.75% | — | +13.78% | |
| 42 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.74% | +1.12% | NEW | |
| 43 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.72% | — | -39.12% | |
| 44 | ELV | Elevance Health Inc | Stock-Healthcare | 0.71% | — | — | |
| 45 | COGT | Cogent Biosciences Inc | Stock-Other | 0.70% | -0.03% | — | |
| 46 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.69% | +1.53% | -3.90% | |
| 47 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.65% | — | -6.51% | |
| 48 | HUM | Humana Inc | Stock-Healthcare | 0.65% | +0.35% | NEW | |
| 49 | ✓ | Acelyrin Inc | Stock-Other | 0.65% | — | -25.05% | |
| 50 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.62% | — | +627.93% |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 92 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LENZ, LLY, BOLD) accounted for 55.1% of total reported equity market value during Q1 2024.
During Q1 2024, Sectoral Asset Management Inc's top holdings by market value included LENZ (9.4%)、LLY (7.8%)、BOLD (4.8%). The largest single position, LENZ, represented 9.4% of total portfolio value.
In Q1 2024, Sectoral Asset Management Inc made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.